Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ribomic, Inc. ( (JP:4591) ) has issued an update.
RIBOMIC Inc. reported non-consolidated results for the nine months to December 31, 2025, with operating revenue effectively at zero and a net loss of ¥763 million, though the per-share loss narrowed from ¥18.88 to ¥15.86 year on year. Total assets rose to ¥3.38 billion and the equity ratio remained high at 94.2%, but the company continues to suspend dividends and forecasts a full-year loss of ¥1.28 billion on modest revenue of ¥3 million.
The biotech firm’s persistent losses underscore the long development timelines and funding demands typical of early-stage drug discovery companies, even as its strong equity ratio suggests a still-solid balance sheet. Shareholders face continued dilution risk, with issued shares rising to 54.3 million, and no near-term income returns, as management maintains a zero-dividend policy while prioritizing R&D and long-term pipeline value creation.
The most recent analyst rating on (JP:4591) stock is a Hold with a Yen83.00 price target. To see the full list of analyst forecasts on Ribomic, Inc. stock, see the JP:4591 Stock Forecast page.
More about Ribomic, Inc.
RIBOMIC Inc., listed on the Tokyo Stock Exchange under code 4591, operates in the biotechnology and pharmaceutical sector. The company focuses on developing nucleic acid-based therapeutics and related technologies, targeting unmet medical needs and niche markets in drug discovery and development.
Average Trading Volume: 1,001,335
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.51B
See more data about 4591 stock on TipRanks’ Stock Analysis page.